Gastrointestinal malignancies and cardiovascular diseases-Non-negligible comorbidity in an era of multi-antithrombotic drug use

Journal of Cardiology

Volumn 58, Issue 3, 2011, Pages 199-207

  Ishizaka, Nobukazu ^a   Sakamoto, Aiko ^b   Fujishiro, Mitsuhiro ^b   Nagai, Ryozo ^b   Koike, Kazuhiko ^b  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antithrombotic medication; Gastrointestinal malignancy; Gastrointestinal screening; Peptic ulcers

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PROTON PUMP INHIBITOR; TICLOPIDINE; WARFARIN;

ABDOMINAL AORTA ANEURYSM; ANEMIA; BLEEDING; CANCER SCREENING; CARDIOVASCULAR DISEASE; COLON DISEASE; COLORECTAL CANCER; COMORBIDITY; DIGESTIVE SYSTEM CANCER; DRUG USE; DUODENUM DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; OCCULT BLOOD; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; STOMACH DISEASE;

CARDIOVASCULAR DISEASES; COMORBIDITY; FIBRINOLYTIC AGENTS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL NEOPLASMS; HUMANS; OCCULT BLOOD; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS;

EID: 82855161333     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.08.004     Document Type: Review

References (69)

1. Antman E.M., Wiviott S.D., Murphy S.A., Voitk J., Hasin Y., Widimsky P., Chandna H., Macias W., McCabe C.H., Braunwald E. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008, 51:2028-2033.
2. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey D.E., Chavey W.E., Fesmire F.M., Hochman J.S., Levin T.N., Lincoff A.M., Peterson E.D., Theroux P., Wenger N.K., Wright R.S., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007, 50:e1-e157.
3. Weisman S.M., Graham D.Y. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002, 162:2197-2202.
4. Ezekowitz M.D., Bridgers S.L., James K.E., Carliner N.H., Colling C.L., Gornick C.C., Krause-Steinrauf H., Kurtzke J.F., Nazarian S.M., Radford M.J., Rickles F.R., Shabetai R., Deykin D. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992, 327:1406-1412. for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.
5. Lip G.Y., Huber K., Andreotti F., Arnesen H., Airaksinen K.J., Cuisset T., Kirchhof P., Marin F. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010, 103:13-28.
6. Pirmohamed M., James S., Meakin S., Green C., Scott A.K., Walley T.J., Farrar K., Park B.K., Breckenridge A.M. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004, 329:15-19.
7. Ko D.T., Yun L., Wijeysundera H.C., Jackevicius C.A., Rao S.V., Austin P.C., Marquis J.F., Tu J.V. Incidence, predictors, and prognostic implications of hospitalization for late bleeding after percutaneous coronary intervention for patients older than 65 years. Circ Cardiovasc Interv 2010, 3:140-147.
8. Lin K.J., Hernandez-Diaz S., Rodriguez L.A. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology 2011.
9. Allison J.E., Sakoda L.C., Levin T.R., Tucker J.P., Tekawa I.S., Cuff T., Pauly M.P., Shlager L., Palitz A.M., Zhao W.K., Schwartz J.S., Ransohoff D.F., Selby J.V. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007, 99:1462-1470.
10. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly P.A., Themeles E., Varrone J., Wang S., Alings M., Xavier D., Zhu J., Diaz R., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
11. Connolly S.J., Eikelboom J., Joyner C., Diener H.C., Hart R., Golitsyn S., Flaker G., Avezum A., Hohnloser S.H., Diaz R., Talajic M., Zhu J., Pais P., Budaj A., Parkhomenko A., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
12. Harjai K.J., Shenoy C., Orshaw P., Usmani S., Boura J., Mehta R.H. Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) Investigators. Circ Cardiovasc Interv 2011.
13. Tran A., Cheng-Lai A. Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin. Cardiol Rev 2011, 19:154-161.
14. Denis B., Gendre I., Aman F., Ribstein F., Maurin P., Perrin P. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial). Eur J Cancer 2009, 45:3282-3290.
15. Young P.E., Ray Q.P., Hwang I., Kikendall J.W., Gentry A.B., Skopic A., Cash B.D. Gastroenterologists' interpretation of CTC: a pilot study demonstrating feasibility and similar accuracy compared with radiologists' interpretation. Am J Gastroenterol 2009, 104:2926-2931.
16. Inoue M., Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J 2005, 81:419-424.
17. Bhatt D.L., Cryer B.L., Contant C.F., Cohen M., Lanas A., Schnitzer T.J., Shook T.L., Lapuerta P., Goldsmith M.A., Laine L., Scirica B.M., Murphy S.A., Cannon C.P. COGENT investigators clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010, 363:1909-1917.
18. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., Menard J., Rahn K.H., Wedel H., Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755-1762.
19. Serrano P., Lanas A., Arroyo M.T., Ferreira I.J. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002, 16:1945-1953.
20. Huang E.S., Strate L.L., Ho W.W., Lee S.S., Chan A.T. A prospective study of aspirin use and the risk of gastrointestinal bleeding in men. PLoS One 2010, 5:e15721.
21. Ibanez L., Vidal X., Vendrell L., Moretti U., Laporte J.R. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther 2006, 23:235-242.
22. Fork F.T., Lafolie P., Toth E., Lindgarde F. Gastroduodenal tolerance of 75mg clopidogrel versus 325mg aspirin in healthy volunteers. A gastroscopic study. Scand J Gastroenterol 2000, 35:464-469.
23. Hsu P.I., Lai K.H., Liu C.P. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology 2011, 140:791-798.
24. García Rodríguez L.A., Lin K.J., Hernandez-Diaz S., Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011, 123:1108-1115.
25. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
26. Lanas A., García Rodríguez L.A., Arroyo M.T., Bujanda L., Gomollon F., Forne M., Aleman S., Nicolas D., Feu F., Gonzalez-Perez A., Borda A., Castro M., Poveda M.J., Arenas J. Investigators of the Asociación Española de Gastroenterología (AEG) effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007, 102:507-515.
27. Abraham N.S., Hlatky M.A., Antman E.M., Bhatt D.L., Bjorkman D.J., Clark C.B., Furberg C.D., Johnson D.A., Kahi C.J., Laine L., Mahaffey K.W., Quigley E.M., Scheiman J., Sperling L.S., Tomaselli G.F. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010, 122:2619-2633.
28. Bini E.J., Rajapaksa R.C., Weinshel E.H. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol 2005, 100:1586-1592.
29. Greenberg P.D., Cello J.P., Rockey D.C. Relationship of low-dose aspirin to GI injury and occult bleeding: a pilot study. Gastrointest Endosc 1999, 50:618-622.
30. Mandel J.S., Bond J.H., Church T.R., Snover D.C., Bradley G.M., Schuman L.M., Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993, 328:1365-1371.
31. Levin B., Lieberman D.A., McFarland B., Andrews K.S., Brooks D., Bond J., Dash C., Giardiello F.M., Glick S., Johnson D., Johnson C.D., Levin T.R., Pickhardt P.J., Rex D.K., Smith R.A., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008, 134:1570-1595.
32. Greenberg P.D., Cello J.P., Rockey D.C. Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease. Am J Med 1996, 100:598-604.
33. Pengo V., Legnani C., Noventa F., Palareti G. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost 2001, 85:418-422.
34. Kahi C.J., Imperiale T.F. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am J Med 2004, 117:837-841.
35. Carey R.J. Warfarin-induced rectal bleeding as clue to colon cancer. Lancet 1984, 1:505-506.
36. McCall K.L., MacLaughlin E.J. Warfarin-associated bleeding complication saved life. Pharmacotherapy 2002, 22:265-268.
37. Sawhney M.S., McDougall H., Nelson D.B., Bond J.H. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci 2010, 55:1637-1642.
38. Clarke P., Jack F., Carey F.A., Steele R.J. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening. Colorectal Dis 2006, 8:389-392.
39. Norton S.A., Armstrong C.P. Lower gastrointestinal bleeding during anticoagulant therapy: a life-saving complication?. Ann R Coll Surg Engl 1997, 79:38-39.
40. Wysota B.A., Gorard D.A. Colonic carcinoma unmasked by dual antiplatelet therapy. Eur J Intern Med 2008, 19:558.
41. Chan A.O., Lam K.F., Tong T., Siu D.C., Jim M.H., Hui W.M., Lai K.C., Yuen M.F., Lam S.K., Wong B.C. Coexistence between colorectal cancer/adenoma and coronary artery disease: results from 1382 patients. Aliment Pharmacol Ther 2006, 24:535-539.
42. Chan A.O., Jim M.H., Lam K.F., Morris J.S., Siu D.C., Tong T., Ng F.H., Wong S.Y., Hui W.M., Chan C.K., Lai K.C., Cheung T.K., Chan P., Wong G., Yuen M.F., et al. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA 2007, 298:1412-1419.
43. Larsson S.C., Orsini N., Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:1679-1687.
44. Neugut A.I., Lebwohl B. Is the prevalence of colorectal neoplasm higher in patients with coronary artery disease?. Nat Clin Pract Oncol 2008, 5:248-249.
45. Yang S.Y., Kim Y.S., Chung S.J., Song J.H., Choi S.Y., Park M.J., Yim J.Y., Lim S.H., Kim D., Kim C.H., Kim J.S., Song I.S. Association between colorectal adenoma and coronary atherosclerosis detected by CT coronary angiography in Korean men; a cross-sectional study. J Gastroenterol Hepatol 2010, 25:1795-1799.
46. Muller A.D., Sonnenberg A., Wasserman I.H. Diseases preceding colon cancer. A case-control study among veterans. Dig Dis Sci 1994, 39:2480-2484.
47. Guzzetti S., Costantino G., Sada S., Fundaro C. Colorectal cancer and atrial fibrillation: a case-control study. Am J Med 2002, 112:587-588.
48. Hutten B.A., Prins M.H., Gent M., Ginsberg J., Tijssen J.G., Buller H.R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000, 18:3078-3083.
49. Lainscak M., Dagres N., Filippatos G.S., Anker S.D., Kremastinos D.T. Atrial fibrillation in chronic non-cardiac disease: where do we stand?. Int J Cardiol 2008, 128:311-315.
50. Martin R., Delgado J.M., Molto J.M., Vicent J.M., Manzanares R., Insa R., Matias-Guiu J. Cardiovascular reflexes in patients with malignant disease. Ital J Neurol Sci 1992, 13:125-129.
51. Darnell R.B. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci U S A 1996, 93:4529-4536.
52. Massie B.M., Collins J.F., Ammon S.E., Armstrong P.W., Cleland J.G., Ezekowitz M., Jafri S.M., Krol W.F., O'Connor C.M., Schulman K.A., Teo K., Warren S.R. WATCH trial investigators randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009, 119:1616-1624.
53. Pons F., Lupon J., Urrutia A., Gonzalez B., Crespo E., Diez C., Cano L., Cabanes R., Altimir S., Coll R., Pascual T., Valle V. Mortality and cause of death in patients with heart failure: findings at a specialist multidisciplinary heart failure unit. Rev Esp Cardiol 2010, 63:303-314.
54. Jong P., Vowinckel E., Liu P.P., Gong Y., Tu J.V. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002, 162:1689-1694.
55. Dunlay S.M., Weston S.A., Jacobsen S.J., Roger V.L. Risk factors for heart failure: a population-based case-control study. Am J Med 2009, 122:1023-1028.
56. Morrison D.S., Batty G.D., Kivimaki M., Smith G., Marmot M., Shipley M. Risk factors for colonic and rectal cancer mortality: evidence from 40 years' follow-up in the Whitehall I study. J Epidemiol Community Health 2010, 1.
57. Tribouilloy C., Buiciuc O., Rusinaru D., Malaquin D., Levy F., Peltier M. Long-term outcome after a first episode of heart failure. A prospective 7-year study. Int J Cardiol 2010, 140:309-314.
58. Lobbato V.J., Rothenberg R.E., LaRaja R.D., Georgiou J. Coexistence of abdominal aortic aneurysm and carcinoma of the colon: a dilemma. J Vasc Surg 1985, 2:724-726.
59. Konno H., Kaneko H., Hachiya T., Maruo Y., Tanaka T., Suzuki S., Nakamura S., Baba S. Surgical management for a malignancy of the digestive organs accompanied with an abdominal aortic aneurysm. Surg Today 1998, 28:988-991.
60. Yamamoto K., Miyata T., Nagawa H. The high prevalence of colorectal neoplasms in preoperative patients with abdominal aortic aneurysm or peripheral artery disease. Eur J Vasc Endovasc Surg 2007, 33:397-400.
61. Morikawa T., Kato J., Yamaji Y., Wada R., Mitsushima T., Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005, 129:422-428.
62. Segnan N., Senore C., Andreoni B., Arrigoni A., Bisanti L., Cardelli A., Castiglione G., Crosta C., DiPlacido R., Ferrari A., Ferraris R., Ferrero F., Fracchia M., Gasperoni S., Malfitana G., et al. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J Natl Cancer Inst 2005, 97:347-357.
63. Fiotti N., Altamura N., Cappelli C., Schillan M., Guarnieri G., Giansante C. Long term prognosis in patients with peripheral arterial disease treated with antiplatelet agents. Eur J Vasc Endovasc Surg 2003, 26:374-380.
64. Komori K., Okadome K., Funahashi S., Itoh H., Sugimachi K. Surgical strategy of concomitant abdominal aortic aneurysm and gastric cancer. J Vasc Surg 1994, 19:573-576.
65. Nora J.D., Pairolero P.C., Nivatvongs S., Cherry K.J., Hallett J.W., Gloviczki P. Concomitant abdominal aortic aneurysm and colorectal carcinoma: priority of resection. J Vasc Surg 1989, 9:630-635. discussion 635-636.
66. Robinson G., Hughes W., Lippey E. Abdominal aortic aneurysm and associated colorectal carcinoma: a management problem. Aust N Z J Surg 1994, 64:475-478.
67. Reicher-Reiss H., Jonas M., Goldbourt U., Boyko V., Modan B. Selectively increased risk of cancer in men with coronary heart disease. Am J Cardiol 2001, 87:459-462. A456.
68. Goda A., Yamashita T., Suzuki S., Ohtsuka T., Uejima T., Oikawa Y., Yajima J., Koike A., Nagashima K., Kirigaya H., Sagara K., Ogasawara K., Isobe M., Sawada H., Aizawa T. Heart failure with preserved versus reduced left ventricular systolic function: a prospective cohort of Shinken Database 2004-2005. J Cardiol 2010, 55:108-116.
69. Tsuchihashi-Makaya M., Matsuo H., Kakinoki S., Takechi S., Tsutsui H. Rationale and design of the Japanese Heart Failure Outpatients Disease Management and Cardiac Evaluation (J-HOMECARE). J Cardiol 2011.